The Nosology and Etiology of Leukodystrophies of Unknown Causes
|ClinicalTrials.gov Identifier: NCT00889174|
Recruitment Status : Completed
First Posted : April 28, 2009
Last Update Posted : October 19, 2017
- A leukodystrophy is a disease affecting the white matter of the brain. The white matter conducts electricity from one part of the brain to the other. If the insulation, or myelin, is damaged, the brain s electrical pathways will not work properly. Researchers are trying to identify what causes leukodystrophy.
- To collect detailed clinical characterizations, including histories, physical examinations, biochemical tests, genetic studies, and neurophysiologic and neuroimaging studies in patients with unclassified leukodystrophies to comprehensively characterize such patients and obtain comparative clinical profiles.
- To collect detailed clinical characterizations, including histories, physical examinations, biochemical tests, genomic and proteomic tissue, and neurophysiologic and neuroimaging studies in patients with known leukodystrophies to investigate the underlying pathogenesis of these disorders.
- To better understand leukodystrophies of unknown cause and to identify the part of the DNA of the patient with leukodystrophy that is causing the problem.
Any individual with a known or suspected leukodystrophy is eligible to participate in this protocol, including
- Patients with white matter disease that is unclassified or of unknown cause, including but not limited to leukoencephalopathies with calcifications, leukoencephalopathies with cysts, leukoencephalopathies with hypomyelination, and leukoencephalopathies with brainstem involvement.
- Parents or siblings of these subjects.
- Exclusion criteria include patients too ill to travel to the Clinical Center and patients for whom the leukoencephalopathy is felt to be secondary to an acquired cause (for example, traumatic or infectious).
- Patients will be seen either as an inpatient or outpatient depending on the tests that are planned. Patients may need to stay at the Clinical Center for 3 to 5 days.
The following tests will be conducted as part of standard clinical care:
- Physical and neurological examinations, including blood and urine tests.
- Magnetic resonance based studies to produce a picture of the patient s brain (under general anesthesia).
- Spinal tap to measure chemicals in the spinal fluid (under general anesthesia in young children).
- Nerve biopsy, if the peripheral nerves are affected, or muscle biopsy, if the cells called the mitochondria or the muscles are involved (both under general anesthesia).
The following studies may be performed as part of participation in the research:
- Blood, urine, spinal fluid, or muscle to understand the proteins, DNA, and molecules in these tissues.
- Skin biopsy to grow (in culture) skin cells and to analyze the skin microscopically.
- DNA studies to find new genes responsible for leukodystrophies and to better understand these diseases.
- Participation should be based on an interest to help further the research on leukodystrophies. Specific information about a patient s present or future health risks may not be gained.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||76 participants|
|Official Title:||Leukodystrophies of Unknown Cause|
|Study Start Date :||April 24, 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889174
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||William A Gahl, M.D.||National Human Genome Research Institute (NHGRI)|